EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Assessment of HBV variants and novel viral and immune biomarkers in chronic hepatitis B patients with metabolic dysfunction associated steatotic liver disease

Nishi H Patel iD, Aaron Lucko, Alicia Vachon, Karen E Doucette, Alnoor Ramji, Laura Sycuro, Trushar R Patel iD, Kris Chadee, Maitreyi Raman, Guido van Marle, Carla Osiowy, Carla S Coffin iD

Journal of Viral Hepatitis · 2024

DOI: 10.1111/jvh.13979 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Viral Hepatitis, 2024. Verfasst von Nishi H Patel und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Biomarkers, Fatty Liver, Hepatitis B virus. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CIHR, Wellcome Trust, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Co‐existing chronic hepatitis B virus (CHB) infection and metabolic dysfunction associated steatotic liver disease (MASLD) can exert complex effects on hepatic metabolism, requiring mechanistic study. CHB participants were assessed for MASLD and the impact of hepatic steatosis/metabolic syndrome (MetS) on novel viral and immunological markers. In this prospective, cohort study, untreated CHB subjects were assessed for liver disease by non‐invasive tests (i.e. FibroScan, controlled attenuation parameter, CAP). Subjects were tested for cytokines and IFN‐γ ELISPOT assay to HBV Surface (S) and Core (C) proteins. Standard HBV serological, exploratory biomarkers and deep sequencing of HBV S and C genes were performed. In 53 subjects (median age 45 years [SD = 10.6], 35% F, 56% Asian, 20% Black, 3% White), 94% (50) HBeAg negative, 63% genotype B/C, mean HBV DNA 3.2 log 10 IU/mL (SD = 1.8), quantitative HBsAg 2.9 log 10 IU/mL (SD = 1.2) and HBV pgRNA 2.1 log 10 copies/mL (SD = 1.3). In enrolled subjects, the mean ALT was 41.9 U/L (SD = 24.0), FibroScan was 5.7 kPa (SD = 1.9) and CAP was 306.4 dB/m (SD = 49.0). The mean BMI was 28.2 kg/m 2 (SD = 4.2), 20% (11/53) had diabetes, 35% (19/53) dyslipidaemia and 24% (13/53) hypertension. Subjects with MetS and steatosis showed lower HBV markers ( p < .01), higher HBV S diversity ( p = .02) and greater frequency of HBV variants associated with host‐anti‐viral immune escape. Pro‐inflammatory cytokine levels and HBV‐specific cellular responses were higher in participants with hepatic steatosis. In CHB, MASLD/hepatic steatosis was associated with HBV variants and systemic immune responses potentially impacting liver disease progression despite low‐level viraemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicBiomarkersFatty LiverHepatitis B virusHumansMaleMiddle AgedFemaleAdultProspective StudiesCytokinesDNA, ViralMetabolic SyndromeHepatitis B Surface AntigensEnzyme-Linked Immunospot AssayGenotypeViral LoadHepatitis B Core Antigens

Stichwörter der Autor:innen

T‐cell responsebiomarkerschronic hepatitis Bcytokinesmetabolic dysfunction associated steatotic liver disease

Substanzen

BiomarkersCytokinesDNA, ViralHepatitis B Surface AntigensHepatitis B Core Antigens

Autor:innen und Institutionen

  • Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Department of Microbiology, Immunology and Infectious Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
  • Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
  • Division of Gastroenterology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Departments of Chemistry and Biochemistry, University of Lethbridge, Lethbridge, Alberta, Canada.

ORCID-Profile: Nishi H Patel, Trushar R Patel, Carla S Coffin

Förderung

  • CIHR
  • Wellcome Trust
  • Canadian Institutes of Health Research
  • GlaxoSmithKline Biologicals

Zitieren

APA

Patel, N. H., Lucko, A., Vachon, A., Doucette, K. E., Ramji, A., Sycuro, L., Patel, T. R., Chadee, K., Raman, M., van Marle, G., Osiowy, C., & Coffin, C. S. (2024). Assessment of HBV variants and novel viral and immune biomarkers in chronic hepatitis B patients with metabolic dysfunction associated steatotic liver disease. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.13979

Vancouver

Patel NH, Lucko A, Vachon A, Doucette KE, Ramji A, Sycuro L, et al. Assessment of HBV variants and novel viral and immune biomarkers in chronic hepatitis B patients with metabolic dysfunction associated steatotic liver disease. Journal of Viral Hepatitis. 2024. doi:10.1111/jvh.13979

BibTeX
@article{Patel2024,
  author = {Patel, Nishi H and Lucko, Aaron and Vachon, Alicia and Doucette, Karen E and Ramji, Alnoor and Sycuro, Laura and Patel, Trushar R and Chadee, Kris and Raman, Maitreyi and van Marle, Guido and Osiowy, Carla and Coffin, Carla S},
  title = {Assessment of HBV variants and novel viral and immune biomarkers in chronic hepatitis B patients with metabolic dysfunction associated steatotic liver disease},
  journal = {Journal of Viral Hepatitis},
  year = {2024},
  doi = {10.1111/jvh.13979}
}
Kostenlos starten →